Platinib: an innovative kinase inhibitor targeting RET fusions and mutations

Pralsetinib is an innovative kinase inhibitor that specifically targets wild-type RET as well as oncogenic RET fusions and mutations. These specific RET mutations can overactivate downstream signaling pathways, thereby driving abnormal cell proliferation and ultimately leading to tumor formation. Platinib has demonstrated significant anti-tumor effects in cell and animal models, particularly in the following two conditions:

1. First of all, platinib is widely used to treat metastatic RET fusion-positive non-small cell lung cancer (NSCLC). Platinib offers a new treatment option for adult patients suffering from this disease.

2. Secondly, for patients 12 years old and older with advanced or metastatic RET fusion-positive thyroid cancer, platinib also shows its therapeutic value. Platinib provides an effective treatment option for both adult and pediatric patients who require systemic therapy and are unresponsive or intolerant to radioactive iodine therapy.

Platinib is available in the form of oral capsules for patient convenience. The recommended dose is once daily, 400 mg each time and should be taken on an empty stomach. To ensure optimal absorption of the medication, patients should avoid eating for at least 2 hours before taking the medication and for at least 1 hour after taking the medication. However, there are adverse effects associated with the use of platinib that need to be noted. These reactions may include fatigue, constipation, musculoskeletal pain, hypertension, and abnormal laboratory test results. Therefore, while taking platinib, patients should pay close attention to their physical condition and promptly communicate with their doctors about any discomfort or abnormal reactions.